ZENTALIS PHARMACEUTICALS INC's ticker is ZNTL and the CUSIP is 98943L107. A total of 142 filers reported holding ZENTALIS PHARMACEUTICALS INC in Q2 2024. The put-call ratio across all filers is 0.11 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $463,749 | -56.4% | 113,386 | +68.0% | 0.00% | – |
| Q1 2024 | $1,063,360 | +11.1% | 67,472 | +6.8% | 0.00% | – |
| Q4 2023 | $957,117 | -80.8% | 63,176 | -74.6% | 0.00% | -100.0% |
| Q3 2023 | $4,997,226 | +27.2% | 249,114 | +9.1% | 0.00% | 0.0% |
| Q2 2023 | $3,927,396 | 0.0% | 228,337 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $3,927,396 | -18.8% | 228,337 | -4.9% | 0.00% | -33.3% |
| Q4 2022 | $4,833,761 | -99.9% | 240,008 | +6.2% | 0.00% | 0.0% |
| Q3 2022 | $4,892,907,000 | +20.5% | 225,896 | +56.3% | 0.00% | +50.0% |
| Q2 2022 | $4,060,310,000 | -32.2% | 144,495 | +11.3% | 0.00% | -33.3% |
| Q1 2022 | $5,987,634,000 | -48.2% | 129,771 | -5.7% | 0.00% | -25.0% |
| Q4 2021 | $11,565,311,000 | +754.9% | 137,584 | +577.7% | 0.00% | +300.0% |
| Q3 2021 | $1,352,859,000 | +26.5% | 20,301 | +1.0% | 0.00% | – |
| Q2 2021 | $1,069,480,000 | +40.0% | 20,103 | +14.2% | 0.00% | – |
| Q1 2021 | $763,664,000 | +27.9% | 17,600 | +53.0% | 0.00% | – |
| Q4 2020 | $597,310,000 | – | 11,500 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Mayo Clinic | 187,143 | $765,415 | 25.27% |
| Decheng Capital LLC | 3,070,442 | $12,558,107 | 3.85% |
| MPM BioImpact LLC | 1,450,000 | $5,930,500 | 0.92% |
| TYBOURNE CAPITAL MANAGEMENT (HK) LTD | 961,486 | $3,932,478 | 0.80% |
| Eventide Asset Management | 8,547,896 | $34,960,895 | 0.60% |
| 5AM Venture Management, LLC | 490,000 | $2,004,100 | 0.45% |
| Matrix Capital Management Company, LP | 13,959,973 | $57,096,290 | 0.44% |
| Values First Advisors, Inc. | 74,925 | $306,443 | 0.18% |
| Boxer Capital, LLC | 450,000 | $1,840,500 | 0.10% |
| GSA CAPITAL PARTNERS LLP | 255,201 | $1,044 | 0.07% |